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Abstract
Background: Men with gynecomastia may suffer from absolute or relative estrogen excess and
their risk of different malignancies may be increased. We tested whether men with gynecomastia
were at greater risk of developing cancer.
Methods: A cohort was formed of all the men having a histopathological diagnosis of gynecomastia
at the Department of Pathology, University of Lund, following an operation for either uni- or
bilateral breast enlargement between 1970–1979. All possible causes of gynecomastia were
accepted, such as endogenous or exogenous hormonal exposure as well as cases of unknown
etiology. Prior to diagnosis of gynecomastia eight men had a diagnosis of prostate carcinoma, two
men a diagnosis of unilateral breast cancer and one had Hodgkin's disease. These patients were
included in the analyses. The final cohort of 446 men was matched to the Swedish Cancer Registry,
Death Registry and General Population Registry.
Results: At the end of the follow up in December 1999, the cohort constituted 8375.2 person
years of follow-up time. A total of 68 malignancies versus 66.07 expected were observed; SIR =
1.03 (95% CI 0.80–1.30). A significantly increased risk for testicular cancer; SIR = 5.82 (95% CI
1.20–17.00) and squamous cell carcinoma of the skin; SIR = 3.21 (95% CI 1.71–5.48) were noted.
The increased risk appeared after 2 years of follow-up. A non-significantly increased risk for
esophageal cancer was also seen while no new cases of male breast cancer were observed.
However, in the prospective cohort, diagnostic operations for gynecomastia may substantially have
reduced this risk
Conclusions: There is a significant increased risk of testicular cancer and squamous cell carcinoma
of the skin in men who have been operated on for gynecomastia.
Background
Gynecomastia is a benign condition appearing both uni-
and bilaterally. It is more common during some time pe-
riods in life, such as early puberty and late adulthood [1].
Beside an endogenous hormonal imbalance in estrogen/
androgen ratio, drugs having estrogenic effects or diseases
associated with injuries to gonads or liver affecting the es-
trogen/androgen ratio may predispose to gynecomastia
[2–4]. Also, many anti-psychotic drugs may induce hyper-
prolactinemia and thus gynecomastia. It has been claimed
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that gynecomastia is more common among men who lat-
er develop testicular cancer and breast cancer [5–12].
Sometimes the treatment of malignancies may be the
cause for gynecomastia, such as oestrogen treatment in
prostate carcinoma and cytostatic treatment in various
malignancies [13–16].
The increased risk for malignant tumours with gyneco-
mastia has previously been described in some case-con-
trol studies. However, no earlier prospective study has
been published. In order to elucidate the possible adverse
or protective effect on malignancy risk of gynecomastia we
formed a prospective cohort of men of whom a his-
topathological diagnosis had been obtained through an
operative biopsy.
Methods
Four hundred forty five men who had been operated for
diagnostic purpose due to unilateral or bilateral gyneco-
mastia in 1970–79 and of whom the pathology specimens
had been sent for diagnosis to the Department of Pathol-
ogy, University Hospital, Lund, Sweden, were included in
the cohort. During this time period diagnostic (open) bi-
opsies were very common in men with breast enlargement
to exclude malignant processes. Later the operative biopsy
has been replaced with fine needle biopsies. The Patholo-
gy Department has an exclusive population based accrual
of specimen in the South-West of the South Swedish
Health Care Region. In this cohort 198 (44.5 %) men
were older than 50 years and 73 (16.4 %) were younger
than 20 years of age at time of diagnostic operation for
gynecomastia (Table 1).
With the help of the unique personal identification
number the vital status and the cancer incidence up to age
99 years of these referents were then identified from the
population based Census Registry, the Cause of Death
Registry and the Swedish Cancer Registry (South Swedish
Regional and the National Swedish Tumour Registry).
Any individual could have had more than one tumour
registered. The vital status was determined up to Jan 1st,
2000. The median follow up time was 266 months, i.e.
22.2 years. No subject was lost to follow up. During the
follow up time, 208 men had died and none emigrated.
The observed versus expected numbers of various malig-
nant tumours were then calculated using reference data
from the southern health care region. Cause specific
standardised incidence ratios (SIRs) and 95 % confidence
intervals (CIs) were calculated. The observed number of
cancer cases was assumed to follow a Poisson-distribu-
tion. Hence, both 95% confidence intervals for the SIR's
and the test hypothesis SIR = 1 (i.e. the cancer incidence is
the same in both populations) were based on the Poisson
distribution. The term "significant" refers to a p value of
0.05. All tests were two tailed.
Results
In table 2 the observed and expected numbers of malig-
nant tumours, the SIRs and the 95 % CIs for all malignant
tumours and different tumour types are shown. Men with
gynecomastia had an overall risk for malignant tumours
similar to that in the reference population; i.e. 68 ob-
served versus 66.07 expected cases, SIR = 1.03 (95% CI
0.80–1.30). The risk for testicular cancer in the gyneco-
mastia patients was significantly increased; 3 observed
versus 0.52 expected, SIR = 5.82, (95% CI 1.20–17.00).
Also, there were13 observed cases of squamous cell carci-
Table 1: Number of individuals are shown in relation to age at inclusion in the cohort and age at last follow up or death.
Number of men at inclusion Number of men at last follow up or death
10–14 18 0
15–19 57 0
20–24 54 0
25–29 36 1
30–34 23 2
35–39 23 22
40–44 15 49
45–49 21 48
50–54 23 48
55–59 25 36
60–64 29 27
65–69 35 29
70–74 43 39
75–79 31 45
=80 12 99BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/26
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noma of the skin versus 4.06 expected, SIR = 3.21, (95%CI
1.71–5.48). Three men developed esophageal cancer ver-
sus 0.78 expected, giving a SIR of 3.82, (95% CI 0.79–
11.17), which does not reach the defined significance lev-
el. The risk for prostate carcinoma was unaltered and no-
body developed breast cancer during the follow-up. A
decreased risk was observed for rectal carcinoma 0 cases
versus 3.57 expected, SIR = 0.00 (95%CI 0.00–1.03).
In table, 3 the SIRs for all malignancies and separately for
testicular, esophageal and squamous skin cancer are pre-
sented in relation to the time interval since diagnosis of
gynecomastia. No increased risk for any malignancy was
seen within the first two years following gynecomastia di-
agnosis. An increased risk was seen for testicular cancer,
esophageal cancer and skin cancer after two years of fol-
low up. Whilst the risk of skin and esophageal cancer in-
creased with longer follow up, the risk for testicular cancer
remained the same.
In table 4 the SIRs for testicular, esophageal and squa-
mous skin cancer are shown associated with the age at di-
agnosis and age during follow. The risk for testicular
cancer was significantly increased only in men with gyne-
comastia diagnosed before the age of 50 years and with
follow up to the age of 50 years; SIR = 6.71(95%CI 1.38–
19.60). The risk for esophageal cancer was significantly in-
creased in men with gynecomastia diagnosed above 50
years of age, SIR = 4.75 (95%CI 1.00–13.90). The risk for
skin cancer was increased in men with diagnosis of gyne-
comastia at any age but with a follow up extending after
50 years of age. Increased risk of squamous skin cancer oc-
curred both in unilateral and bilateral cases while testicu-
Table 2: Risk of malignant tumours in men up to age 99 after a histopathological verified diagnosis of gynecomastia 1970–79. Follow up 
time includes 1970–1999 (8375.2 years). The cohort consists of 446 men.
Diagnosis OBS EXP SIR 95% Confidence interval
140–209 All malignant tumours 68 66.07 1.03 0.80 1.30
140 Lip 1 0.70 1.43 0.04 7.97
141_3_4 Oral cavity 0 0.51 0.00 0.00 7.18
142 Parotid glands 0 0.19 0.00 0.00 19.71
145–148 Pharynx, hypopharynx 0 0.42 0.00 0.00 8.69
150 Esophagus 3 0.78 3.82 0.79 11.17
151 Stomach 3 4.09 0.73 0.15 2.15
153 Colon 7 5.43 1.29 0.52 2.66
154 Rectum 0 3.57 0.00 0.00 1.03
1550 Liver and intrahepatic ducts 1 0.94 1.06 0.03 5.90
1551–1559 Gallblader & bile ducts 1 0.67 1.50 0.04 8.34
157 Pancreas 1 1.95 0.51 0.01 2.86
160 Nasal cavities & sinus 0 0.13 0.00 0.00 27.71
161 Larynx 0 0.65 0.00 0.00 5.67
1620–1621 Trachea & lung 6 6.31 0.95 0.35 2.07
1622 Mesothelioma 0 0.31 0.00 0.00 12.04
170 Male breast cancer 0 0.09 0.00 0.00 42.96
177 Prostate 16 16.21 0.99 0.56 1.60
178 Testicle 3 0.52 5.82 1.20 17.00
180 Kidney 1 2.18 0.46 0.01 2.55
181 Urinary bl,.urinary tc. 1 4.85 0.21 0.01 1.15
190 Melanoma 0 1.73 0.00 0.00 2.1
191 Skin excl melanoma 13 4.06 3.21 1.71 5.48
193 Brain & nervous system 1 1.71 0.59 0.01 3.26
194 Thyroid 0 0.30 0.00 0.00 12.43
196–197 Bone & soft tissue 0 0.49 0.00 0.00 7.59
200+202 Non-Hodgkin's lymphoma 1 1.96 0.51 0.01 2.84
201 Hodgkin's disease 0 0.28 0.00 0.00 12.97
203 Multiple myeloma 0 0.90 0.00 0.00 4.11
Acute leukemia 1 0.54 1.86 0.05 10.38
204.1 Chr. lymph. leukemia 0 0.74 0.00 0.00 4.98
205.1 Chr myeloid leukemia 0 0.18 0.00 0.00 20.83
208 Polycythemia vera 0 0.17 0.00 0.00 21.67BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/26
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lar cancer was predominantly seen in unilateral cases
(table 5).
Discussion
The present study, being the so far only published pro-
spective investigation in the literature with a maximum
follow up time of 30 years, demonstrates a significantly
increased risk for testicular and squamous skin cancer in
men with a prior histopathological diagnosis of gyneco-
mastia. Also a non-significantly increased risk for esopha-
geal cancer was noted while no cases of male breast cancer
was seen. Overall the male patients with gynecomastia did
not show an incidence of malignancy different to that in
the general population.
Gynecomastia develops in a setting of imbalance between
androgens and estrogens where there is a relative estrogen
excess [2–4]. Gynecomastia is more common at pubertal
ages and in oldermen [1]. This was also evident in our ma-
terial (table 1). It has previously been shown in case series
that testicular cancer may sometimes prior to diagnosis in-
duce gynecomastia due to pathologic HCG secretion [5–
7]. In this prospective series two patients developed testic-
ular seminomas and one patient a testicular teratoma fol-
lowing the diagnosis of gynecomastia years earlier.
Chemotherapy may injure gonadal and hormonal func-
tions and are associated with development of gynecomas-
tia [14–16]. Some drugs, mimicking or having estrogenic
or antiandrogenic effects, may also be associated with de-
velopment of gynecomastia [2–4]. This explains the rather
large group of cases with gynecomastia with a prior diag-
nosis of prostate carcinoma where estrogens have been
used as a treatment. Interestingly in our study there was
no sign of a protective effect for prostate carcinoma due to
the relative estrogen excess.
A rare malignancy, male breast cancer, has in epidemio-
logical studies been associated with prior history of gyne-
comastia [8–12]. In our investigation no prospective cases
of male breast cancer was seen, while two men after they
had developed male breast cancer later developed gyneco-
mastia that was not drug induced in the contralateral
breast. Also one of the cases had gynecomastia surround-
ing the breast tumour at diagnosis. In 44 of the 445 cases
bilateral extirpation of the breast tissue was done and in
the remaining cases a unilateral excision was done. This
surgical removal of breast tissue in men potentially prone
to develop breast carcinomas due to the gynecomastia,
Table 3: SIR values(95% CI) in relation to tumour type and different time intervals of follow up since diagnosis of gynecomastia. Also 
number of individuals and personyears for each interval are shown. The lead time between gynecomastia and tumour diagnosis was for 
esophageal cancer 8 years (6–10 years), skin cancer 6 years (3–25 years) and testicular carcinoma 10 years (3–18) years.
Tumour type Time interval since diagnosis of gynecomastia
0–2 years >2–10 years =10 years overall
all sites 0.15(0.00–0.85) 1.19(0.81–1.68) 1.07(0.75–1.49) 1.03 (0.80–1.30)
testicle 0.00(0.00–116.2) 6.60(0.17–36.76) 6.02(0.73–21.73) 5.82 (1.20–17.00)
esophagus ca 0.00(0.00–46.43) 2.57(0.07–14.35) 6.31(0.76–22.79) 3.82 (0.79–11.17)
skin cancer (melanoma excl.) 0.00(0.00–12.33) 2.23(0.72–5.20) 5.30(2.29–10.43) 3.21(1.71–5.48)
number 443 426 337 445
personyears 870 3076 4428 8375
Table 4: Age at gynecomastia diagnosis and risk of tumours in relation to follow up time. SIR values(95% CI).
Tumour type Age at diagnosis
<50 years >50 years
follow up 0–49 years =50–99 years =50–99 years
testicle 6.71(1.38–19.60) 0.00(0.00–119.54) 0.00(0.00–107.07)
esophagus cancer 0.00(0.00–337.54) 0.00(0.00–27.61) 4.75(1.00–13.90)
skin cancer (melanoma excl.) 0.00(0.00–36.76) 7.87(1.62–22.99) 2.84(1.36–5.23)
number 246 124 197
personyears 4869 1135 2292BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/26
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may have substantially reduced the risk for carcinoma as
prophylactic operations or reduction mammoplastic sur-
gery previously has been shown to reduce the risk of
breast cancer in women [17,18]. Liver injury may be asso-
ciated with gynecomastia [2] and in our series chronic al-
coholism was present in 7 cases of which two had known
cirrhosis. The increased risk of esophagus cancer may be
another indicator of alcoholism and secondary liver inju-
ry in a subset of the patients [19]. All cases of esophageal
cancer occurred in individuals with a gynecomastia diag-
nosis after the age of 50 years. We have no explaination
for the higher risk of squamous cell carcinoma of the skin.
No study has previously associated development of squa-
mous cell carcinoma with gynecomastia and the finding
needs to be confirmed in future studies, although the risk
relationship in our study was strong. The reason for the re-
lationship is unclear as the development of skin tumours
in general has not been associated with hormonal risk fac-
tors. That some skin tumours are due to papilloma virus
infections could lend support to a theory of increased vi-
rus activity/effects in individuals exposed to estrogens as is
the case in cervical carcinoma and its virus related carcino-
genesis due to papilloma virus [20]. Also synergistic ac-
tion between chronic estrogen exposure and the
oncogenes of HPV16 that coordinates squamous carcino-
genesis in the female reproductive tract of K14-HPV16
transgenic mice has been found [21]. HPV16 is however
confined to mucous membranes and it is not known if
other HPV types in a similar matter would interact in the
skin with estrogen. A decreased risk of rectal carcinoma
was noted, and we have no biological explaination for this
finding although it has long been known that females
have a lower death rate and risk of the tumour [22].
It is notable that among the 13 skin tumours 5 occurred
in individuals with multiple squamous cell carcinomas of
the skin. Including tumours occurring prior to gyneco-
mastia 8 individuals of 9 had multiple tumours of the
skin. The age at diagnosis of skin cancer was above 50
years of age in all cases, and the risk increased with longer
follow up and was evident both for cases with a gyneco-
mastia diagnosis before as well as after 50 years of age.
From a clinical point of view it is questionable whether
screening of tumours woul dbe worth while in patients
with gynecomastia. On the other hand, the two tumours
most clearly displaying an increased risk, ie.testicular car-
cinoma and squamous skin cancer rather easily can be
screened by general examination. If also male breast can-
cer is included as a risk a possible clinical work up in a
man presenting with gynecomastia should evaluate the
following points; is there a endogenous or exogenous hor-
monal cause?; has the patient been taking drugs that may
cause gynecomastia?; is there a known accompanying dis-
ease causing a liver or gonadal injury?; can tumour disease
in testis, skin and breast be excluded on clinical grounds?.
For men with a gynecomastia diagnosis a after 50 years of
age the risk of testicular cancer is negligible whilst a gyne-
comastia diagnosis before and after 50 years of age may
both indicate an increased the risk for skin cancer.
Conclusions
In conclusion the prospective investigation confirms an
increased risk for testicular cancerin men with a prior his-
tory of gynecomastia. Also skin cancer and esophageal
cancer were morecommon among men with gynecomas-
tia. No prospective case of male breast carcinoma was
seen, although two male breast cancer cases occurred prior
to gynecomastia diagnosis.
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